Cost-effectiveness of olopatadine in seasonal allergic conjunctivitis treatment

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 2, Issue 6, 2002, Pages 549-554

  Lafuma, Antoine ^a   Smith, Andrew F ^b  

^a University of Oxford ^*  (France)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Allergic conjunctivitis; Antihistaminics; Cost analysis; Olopatadine

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; KETOROLAC; KETOTIFEN; LEVOCABASTINE; LORATADINE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; VASOCONSTRICTOR AGENT;

ABSENTEEISM; ALLERGIC CONJUNCTIVITIS; CLINICAL FEATURE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE DISEASE; EYELID EDEMA; HEALTH CARE COST; HUMAN; HYPEREMIA; KERATITIS; PRURITUS; QUALITY OF LIFE; RELAPSE; REVIEW; SEASONAL VARIATION; TREATMENT INDICATION; WELLBEING;

EID: 0036899442     PISSN: 14737167     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737167.2.6.549     Document Type: Review

References (37)

1. Allansmith MR. Immunology of the external ocular tissues. J. Am. Optom. Assoc. 61, S16-S22 (1990).
2. Friedlander MH, Okumuto M, Kelley L. Diagnosis of allergic conjunctivitis. Arch. Ophthalmol. 102, 1198-1199 (1984).
3. Weeke ER. Epidemiology of hay fever and perennial allergic rhinitis. Monogr. Allergy 21, 1-20 (1987).
4. Smith JL. Epidemiology and natural history of asthma, allergic rhinitis and aropic dermatitis. In: Allergy: principle and practice, Vol 2. Middleton E Jr, Reed CE, Elli E et al. (Eds). CV Mosby, St Louis, MO, USA, 891-929 (1988).
5. Croner S, Kjellman MH. Development of atopic disease in relation to family history and cord blood IgE levels. Pediatr. Allergy Immunol. 1, 14-20 (1990).
6. Naclerio R. Allergic conjunctivitis. N. Engl. J. Med. 325, 860-869 (1991).
7. Dodge R, Burrows B. The prevalence and incidence of asthma and asthma-like symptoms in a general population sample. Am. Rev. Respiratory Disease 122, 567-575 (1980).
8. Abelson MB, Weintraub D. levocabastine eye drops: a new approach for the treatment of allergic conjunctivitis. Eur. J. Ophthalmol. 4(2), 91-101 (1994).
9. Mösges R, Hassan H, Wenzel M. Optimal use of topical agents for allergic conjunctivitis, Biodrugs 8(4), 250-264 (1997).
10. Hingorani M, Lightman S. Therapeutic options in ocular allergic diseases, Drugs 50(2), 206-221 (1995).
11. Ciprandi G, Buscaglia S, Canonica W. Management of allergic conjunctivitis. Clin. Immunother. 5(5), 374-391 (1996).
12. Juniper EF, Thompson AK, Ferrie PJ, Roberts JN. Validation of the standardized version of the Rhino-conjunctivitis Quality of Life Questionnaire. J. Allergy Clin. Immunol. 104, 364-369 (1999).
13. De Graaf-in't Veld T, Koenders S, Garrelds IM, Gerth van Wijk R. Relationship between nasal hyperreactivity, quality of life, and nasal symptoms in perennial rhinitis. J. Allergy Clin. Immunol. 98 508-513 (1996).
14. US Department of Health and Human Services. Asthma and allergies: an optimistic future. DHHS, DHHS publication no. NIH80-388 Bethesda, MD, USA (1980).
15. Dart JKG, Buckley RJ, Monnickendan M, Prasad J. Perennial allergic conjunctivitis: definition, clinical characteristics and prevalence. A comparison with seasonal allergic conjunctivitis. Trans. Ophthalmol. Soc. UK 105(5), 513-520 (1986).
16. McMenamin P. Cost of hay fever in the United States in 1990. Ann. Allergy 73, 35-39 (1994).
17. Weston JH, Udell IJ, Abelson NIB. H1 receptors in the human ocular surface. Invest. Ophthalmol. Vis. Sci. 20(Suppl.), 32 (1980).
18. Abelson MB, Baird RS, Allansmith MR. Tear histamine levels in vernacular conjunctivitis and other ocular inflammations. Ophthalmology 87, 812-814 (1980).
19. Berdy GJ, Abelson MB, George MA. Allergic conjunctivitis: a survey of new antihistamines. J. Ocul. Pharmacol. Ther. 7, 313-324(1991).
20. Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA. Comparative effects of topical ocular antiallergy drugs on human conjunctival mast cells. Ann. Allergy Asthma Immunomodul. 79, 541-545 (1997).
21. Sharif NA, Xu SX, Miller ST et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine, a novel drug for treating ocular allergy disease. J. Pharmacol. Exp. Ther. 278, 1252-1261 (1996).
22. Yanni JM, Stephens DJ, Miller ST et al. The in vitro and in vivo ocular pharmacology of olapatadine an effective anti-allergic/inflammatory agent. J. Ocul. Pharmacol. Ther. 12(4), 389-400 (1996).
23. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am. J. Ophthalmol. 125, 797-804 (1998).
24. Abelson MB, Welch DL, Lanier RQ. An evaluation of onset and duration of action of Patanol compared to Claritin tablets in acute allergic conjunctivitis in the conjunctival allergen challenge model. Act. Ophthalmol. Scand 78, 60-63 (2000).
25. Abelson MB, Lanier RQ The added benefit of local Patanol therapy when combined with systemic Claritin for the inhibition of ocular itching in the conjunctival antigen challenge model. Act. Ophthalmol. Scand. 77, 53-56 (1999).
26. Lanier BQ, Gross RD, Bethany Marks BB, Cockrum PC, Juniper EF. Olopatadine ophthalmic solution adjunctive to loratadine tablets compared with active seasonal allergic conjunctivitis symptoms Ann. Allergy Asthma Immunol. 86, 641-648 (2001).
27. Berdy GJ, Spangler DL, Bensch G, Berdy SS, Brusatti RC. A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1% ophthalmic solution and kerotifen fumarate 0.025% ophthalmic solution in the conjunctival antigen challenge model. Clin. Ther. 22(7), 826-833 (2000).
28. Deschenes J, Discepola M, Abelson M. Comparative evaluation of olopatadine ophthalmic solution (0.1%) versus ketorolac ophthalmic solution (0.5%) in the provocative antigen challenge model. Act. Ophthalmol. Scand. 77,47-52 (1999).
29. Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin. Ther. 22(12), 1462-1472 (2000).
30. Artal MJ, Luna JD, Discepola M. A forced choice comfort study of olopatadine hydrochloride 0.1% versus ketotifen fumarate 0.05%. Act. Ophthalmol. Scand. 78, 64-65 (2000).
31. Aguilar AJ. Comparative study of clinical efficacy and tolerance in seasonal allergic conjunctivitis management with 0.1% olopatadine hydrochloride versus 0.05% ketotifen fumarate. Act. Ophthalmol. Scand. 78, 52-55 (2000).
32. Lafuma A, Fagnani F, Nuijten M, Berdeaux G. Costs and consequences of olopatadine 0.1% versus cromolyn sodium 2% in the treatment of seasonal allergic conjunctivitis, Proceedings of the ISPOR fourth annual European conference, Cannes, France, November 2001. Value in Health 4(6), 514 (2001).
33. Katelaris CH, Ciprandi G, Missotten L, Turner FD, Bertin D, Berdeaux G, and the Internaitonal Olopatadine study group. Efficacy and safey of olopatadine 0.1% ophthalmic solution and cromoglycate sodium 2% ophthalmic solution in seasonal allergic solution, submitted to Clin. Therapeutics (2002).
34. Lafuma A, Fagnani F, Nuijten M, Berdeaux G. Costs and consequences of olopatadine 0.1% versus levocabastin 0.05% in the treatment of seasonal allergic conjunctivitis, Proceedings of the ISPOR fourth annual European conference, Cannes, France, November 2001. Value in Health 4(6), 513 (2001).
35. Bielory L. Update on ocular allergy treatment. Expert Opin. Pharmacother. 3(5) 541-553 (2002).
36. Ray NF, Baraniuk JN, Thamer M et al. Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses. J. Allergy Clin. Immunol. 103(3 Pt 1), 401-407 (1999).
37. Pinto CG, Lafuma A, Fagnani F, Nuijten MJ, Berdeaux G. Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries. Pharmaco Economics 19(3), 256-265 (2001).